Example searches

CLDX Celldex Therapeutics Inc.

Celldex Therapeutics, Inc. engages in the business of development, manufacturing and commercialization of novel therapeutics for human health care. Its drug candidates have the ability to engage the human immune system and directly inhibit tumors to treat specific types of cancer and other diseases. Its pipeline includes Varlilumab, CDX-1140, and CDX-301, and CDX-3379. The company was founded by Anthony S. Marucci and Tibor Keler in 1983 and is headquartered in Hampton, NJ.

Company profile

Ticker
CLDX
Exchange
NASDAQ
Website
www.celldex.com
CEO
Anthony S. Marucci
Employees
Incorporated
Delaware
Location
New Jersey
Fiscal year end
Dec 31
Sector
Health Technology > Medical Specialties
Industry (SIC)
In Vitro & In Vivo Diagnostic Substances
IDEXX Laboratories • Myriad Genetics • Lantheus • Quidel • Neogen • Meridian Bioscience • Oxford Immunotec Global • Achieve Life Sciences • Intellia Therapeutics • Heska ...
Former names
AVANT IMMUNOTHERAPEUTICS INC, T CELL SCIENCES INC
SEC CIK
0000744218
Corporate docs
IRS number
133191702

CLDX stock data

(
)

Investment data

Data from SEC filings
Securities sold
Number of investors

Calendar

6 Aug 20
23 Sep 20
31 Dec 20

News

Financial summary

Financial statements Chart CLDX financial data
Quarter (USD) Jun 20 Mar 20 Sep 19 Jun 19
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD) Dec 19 Dec 18 Dec 17 Dec 16
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from company earnings reports.

Recent insider trades

CLDX insider ownership history Insider history
Date Owner Security Transaction Code 10b5-1 $Price #Shares $Value #Remaining
18 Jun 20 Shoos Karen L. NQSO Common Stock Grant Aquire A No 10.38 11,000 114.18K 11,000
18 Jun 20 Penner Harry JR NQSO Common Stock Grant Aquire A No 10.38 11,000 114.18K 11,000
18 Jun 20 Pepin Ronald Incentive Stock Option Common Stock Grant Aquire A No 10.38 14,400 149.47K 14,400
18 Jun 20 Wright Richard M. Incentive Stock Option Common Stock Grant Aquire A No 10.38 42,000 435.96K 42,000
18 Jun 20 Young Diane C. Incentive Stock Option Common Stock Grant Aquire A No 10.38 72,000 747.36K 72,000
Data from 3, 4 and 5 filings. Stock values as filed, not updated for current price.

Institutional ownership Q2 2020

CLDX institutional ownership history Ownership history
70.1% owned by funds/institutions
13F holders
 Current Prev Q Change
Total holders 74 43 +72.1%
Opened positions 39 7 +457.1%
Closed positions 8 11 -27.3%
Increased positions 12 10 +20.0%
Reduced positions 9 9 –
13F shares
 Current Prev Q Change
Total value 356.45M 5.95M +5886.7%
Total shares 27.42M 3.55M +672.0%
Total puts 211.7K 13.4K +1479.9%
Total calls 795K 39.3K +1922.9%
Total put/call ratio 0.3 0.3 -21.9%
Largest owners
 Shares Value Change
BVF 2.74M $35.62M NEW
RTW Investments 2.61M $33.93M NEW
Redmile 2M $26M NEW
Logos Global Management 2M $26M NEW
Adage Capital Partners GP, L.L.C. 1.75M $22.75M NEW
Ikarian Capital 1.65M $21.42M NEW
Renaissance Technologies 1.64M $21.28M +39.9%
Vivo Capital 1.6M $20.8M NEW
Vanguard 1.3M $16.85M +141.0%
Ra Capital Management 1.15M $14.95M NEW
Largest transactions
 Shares Bought/sold Change
BVF 2.74M +2.74M NEW
RTW Investments 2.61M +2.61M NEW
Redmile 2M +2M NEW
Logos Global Management 2M +2M NEW
Adage Capital Partners GP, L.L.C. 1.75M +1.75M NEW
Ikarian Capital 1.65M +1.65M NEW
Vivo Capital 1.6M +1.6M NEW
Ra Capital Management 1.15M +1.15M NEW
Opaleye Management 1.07M +1.07M NEW
Boxer Capital 1M +1M NEW
Data from 13F filings. Stock values as filed, not updated for current price. Long positions only.

Financial report summary

?
Competition
Pfizer • Immunomedics • Astrazeneca • Roche • Nektar Therapeutics • Novartis • Stemline Therapeutics • Arrogene • Heat Biologics • Tesaro
Content analysis ?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. sophomore Avg
New words: Academy, al, allosteric, ameliorating, asymptomatic, Bartlett, breaking, constituted, continuting, convenient, count, CU, DermNet, dermographism, detection, EAACI, enzyme, etiology, exclusively, exploratory, featured, fourth, frequency, Hautarzt, incidence, infusion, intervention, justify, long, magnitude, mediated, mirror, neutrophil, Org, pancreatic, pending, PK, placebo, plasma, prevalence, profound, randomized, resolved, schedule, secreted, serum, spontaneously, subset, synthesized, tryptase, underwriting, underwritten, untreated, Weller, white
Removed: calculation, cavity, clearance, consolidate, cytotoxic, death, enhance, ensuing, epitope, equal, gene, inactivating, investigating, kill, labor, line, longer, MA, mechanism, Needham, notable, NOTCH, occur, occurred, offer, opened, oral, outlined, overcome, pharmacologic, planning, present, proposed, renewed, sensitivity, sequencing, serve, signaling, sizeable, slower, suggest
From filing 10-Q 2020 Q2

Financial reports

View all
10-Q
2020 Q2
Quarterly report
6 Aug 20
10-Q
2020 Q1
Quarterly report
6 May 20
10-K
2019 FY
Annual report
26 Mar 20
10-Q
2019 Q3
Quarterly report
12 Nov 19
10-Q
2019 Q2
Quarterly report
7 Aug 19
10-Q
2019 Q1
Quarterly report
7 May 19
10-K
2018 FY
Annual report
7 Mar 19
10-Q
2018 Q3
Quarterly report
7 Nov 18
10-Q
2018 Q2
Quarterly report
8 Aug 18
10-Q
2018 Q1
Quarterly report
10 May 18

Current reports

View all
8-K
Other Events
18 Aug 20
8-K
Celldex Provides Corporate Update and Reports Second Quarter 2020 Results
6 Aug 20
8-K
Departure of Directors or Certain Officers
18 Jun 20
8-K
Celldex Therapeutics Announces Proposed Public Offering of Common Stock
17 Jun 20
8-K
Other Events
15 Jun 20
8-K
Other Events
12 Jun 20
8-K
Celldex Provides Corporate Update and Reports First Quarter 2020 Results
6 May 20
8-K
Celldex Provides Corporate Update and Reports Fourth Quarter and Year End 2019 Results
26 Mar 20
8-K
Celldex Provides Corporate Update and Reports Third Quarter 2019 Results
12 Nov 19
8-K
Celldex Provides Corporate Update and Reports Second Quarter 2019 Results
7 Aug 19

Registration and prospectus

View all
S-8
Registration of securities for employees
26 Jun 20
424B5
Prospectus supplement for primary offering
17 Jun 20
424B5
Prospectus supplement for primary offering
15 Jun 20
424B5
Prospectus supplement for primary offering
15 Jun 20
424B5
Prospectus supplement for primary offering
12 Jun 20
S-3/A
Shelf registration (amended)
12 Jun 20
424B5
Prospectus supplement for primary offering
27 Mar 20
S-3
Shelf registration
6 Dec 19
S-8
Registration of securities for employees
21 Jun 19
S-8
Registration of securities for employees
21 Jun 19

Proxies

View all
DEF 14A
Definitive proxy
28 Apr 20
DEFA14A
Additional proxy soliciting materials
7 May 19
DEF 14A
Definitive proxy
26 Apr 19
DEF 14A
Definitive proxy
30 Apr 18
PRE 14A
Preliminary proxy
19 Apr 18
DEF 14A
Definitive proxy
28 Apr 17
PRE 14A
Preliminary proxy
17 Apr 17
DEF 14A
Definitive proxy
21 Apr 16
DEF 14A
Definitive proxy
23 Apr 15
DEF 14A
Definitive proxy
9 Apr 14

Other

View all
EFFECT
Notice of effectiveness
15 Jun 20
CORRESP
Correspondence with SEC
12 Jun 20
UPLOAD
Letter from SEC
12 Dec 19
CT ORDER
Confidential treatment order
20 Apr 18
EFFECT
Notice of effectiveness
13 Feb 17
EFFECT
Notice of effectiveness
13 Feb 17
CORRESP
Correspondence with SEC
9 Feb 17
CORRESP
Correspondence with SEC
9 Feb 17
UPLOAD
Letter from SEC
6 Feb 17
CORRESP
Correspondence with SEC
12 Jan 17

Ownership

View all
SC 13G
Celldex Therapeutics / ADAGE CAPITAL PARTNERS GP, L.L.C. ownership change
24 Jul 20
SC 13G
Celldex Therapeutics / BIOTECHNOLOGY VALUE FUND L P ownership change
26 Jun 20
SC 13G
Celldex Therapeutics / RTW INVESTMENTS ownership change
19 Jun 20
4
Celldex Therapeutics / Samuel Bates Martin ownership change
19 Jun 20
4
Celldex Therapeutics / Margo Heath-Chiozzi ownership change
19 Jun 20
4
Celldex Therapeutics / Sarah Cavanaugh ownership change
19 Jun 20
4
Celldex Therapeutics / Elizabeth Crowley ownership change
19 Jun 20
4
Celldex Therapeutics / RONALD PEPIN ownership change
19 Jun 20
4
Celldex Therapeutics / Richard M. Wright ownership change
19 Jun 20
4
Celldex Therapeutics / Diane C. Young ownership change
19 Jun 20

Patents

View all
GRANT
Utility
Methods of treating by administering anti-kit antibodies
22 Sep 20
Provided herein, in one aspect, are antibodies that immunospecifically bind to a human KIT antigen comprising the fourth and/or fifth extracellular Ig-like domains (that is, D4 and/or D5 domains), polynucleotides comprising nucleotide sequences encoding such antibodies, and expression vectors and host cells for producing such antibodies.
GRANT
Utility
Treatment of eosinophil or mast cell related disorders
15 Sep 20
Provided herein are methods and uses involving antibodies that specifically bind to a KIT receptor tyrosine kinase for managing, treating, or preventing an eosinophil or mast cell related disorder and/or one or more symptoms thereof, for example a mast cell related disorder of the nervous system, e.g., central nervous system, for example neuromyelitis optica (NMO), neuromyelitis optica spectrum disorder (NMOSD), multiple sclerosis (MS), and neurofibromatosis (NF).
GRANT
Utility
Anti-ErbB antibodies and methods of use thereof
18 Aug 20
Provided herein are compositions, methods and uses involving antibodies that bind to ErbB, a receptor tyrosine kinase, and modulate the activity of ErbB.
GRANT
Utility
Use of anti-PD-1 antibody in combination with anti-CD27 antibody in cancer treatment
2 Jun 20
This disclosure provides methods for treating cancer in a subject comprising administering to the subject an anti-PD-1 antibody and an anti-CD27 antibody.
APP
Utility
Anti-ALK Antibodies and Methods for Use Thereof
21 May 20
Provided herein are compositions, methods and uses involving antibodies that specifically bind to ALK, a receptor tyrosine kinase, and modulate the expression and/or activity of ALK.